HRG 2005
Alternative Names: HRG-2005Latest Information Update: 14 Feb 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
Most Recent Events
- 15 Jan 2024 Phase-II clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in China (Inhalation) (NCT06035393)
- 19 Sep 2023 Preclinical trials in Chronic obstructive pulmonary disease in China (Inhalation), prior to September 2023 (NCT06035393)
- 13 Sep 2023 Jiangsu HengRui Medicine plans a phase II trial for Chronic obstructive pulmonary disease in October 2023 (Inhalation) (NCT06035393)